Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04701957
Other study ID # APHP201281
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 30, 2023
Est. completion date March 2027

Study information

Verified date May 2024
Source Assistance Publique - Hôpitaux de Paris
Contact LILAMAND Matthieu, MD PhD
Phone +33140054954
Email matthieu.lilamand@aphp.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The ketogenic diet (KD) is a metabolic shift, which stimulates the liver oxidation of fatty acids to produce ketone bodies. These ketone bodies represent an alternative fuel source for the brain. The benefits of KD in epilepsia have been demonstrated for decades. This diet may also provide benefits in Alzheimer's disease (AD) where neuronal glucose utilization declines from the early stage. Besides, the KD could decrease neuroinflammation, oxidative stress and enhance mitochondrial biogenesis. In murin models of AD, KD or Medium Chain Triglycerides consumption were associated with lower neuroinflammation but also with a diminution of neuropathologic features of AD (amyloid and tau lesions in the brain). Moreover, behavioural effets and improvements in memory and motor function have been highlighted. In humans, recent studies suggest cognitive benefits (memory, executive function) in AD, including in the Mild Cognitive Impairment (MCI) stage. The feasibility and the adherence to the diet proved to be correct, in small samples, in particular in MCI individuals over a short follow-up period (3 to 6 months). This study aims at examining the feasibility of a KD followed-up for one year in participants with early AD (N=70). Change in brain metabolism will be assessed using PET scan after 12 months, comparing KD with control diet. The effects on cognition, quality of life and daily living functioning will be analysed. The safety, nutritional changes and adhesion to the diet will be monitored throughout the study.


Description:

Research context: Alongside the amyloid plaques and neurofibrillary tangles, the neuroinflammation triggered by the central nervous system's innate immune response plays a central role in the pathogenesis of Alzheimer's disease (AD). ß-amyloid deposition and tau lesions are accompanied by activated microglia and astrocytes. These cells release proinflammatory cytokines and chemokines causing chronic neuroinflammation. In turn, neuroinflammation promotes neurodegeneration and ß-amyloid production. Many relationships have been demonstrated not only between glucose metabolism and neuroinflammation, but also between glucose metabolism and AD. Hyperglycemia promotes neuroinflammation leading to oxydative stress and neurodegeneration. Insulinoresistance (e.g. in type 2 diabetes) or low IGF-1 levels are associated with increased ß-amyloid production. In the absence of glucose, the brain may use another fuel: ketogenic bodies (KB) produced by oxydation of fatty acids. The ketogenic diet (KD) (defined by low carbohydrate intake (< 10%) in AD animal models led to a slower cognitive decline, decreased neuroinflammation and amyloid and tau deposition. In humans, the KD is safe and is an efficient validated treatment of drug-resistant epilepsy to decrease the number of seizures and to improve the cognitive development in epileptic children. In AD, although KD is publicized within the community, evidence-based data regarding efficiency is scarce. State of art and preliminary observations: Preclinical studies: - Ketone bodies may play a neuroprotective effect against beta-amyloid toxicity. In cultured hippocampal neurons of rats, the direct application of the ketone ß-hydroxybutyrate in relevant concentrations protects hippocampal neurons from beta-amyloid toxicity. The addition of ß-hydroxybutyrate however, reversed Aß toxicity, acting instead as a growth factor that doubled the number of surviving cells. - In 3xTgAD mice, a ketogenic diet suppressed beta-amyloid and tau pathology in the brain; the ketogenic-fed mice also experienced superior cognitive perfomance compared with control: improved memory. Likewise, in another model of AD (APP/V717I young mice), a KD vs control diet was associated with lower amyloid levels. - Several other animal studies have highlighted the potential clinical benefits of KD: improved visuo-spatial function in aged dogs, improved motor function in amyloid and tau models of mice, in APP/PS1 knock-in mice, or in old rats. Human studies - A clinical trial specifically assessed the feasability of a very high-fat ketogenic diet in participants with AD, with a 3- month follow-up. This diet proved feasible in CDR 0,5 and CDR 1 participants. Moreover, all the participants but one adapted to the diet and achieved ketosis. Study completers showed significant cognitive improvement on the ADAScog scale. - A couple of studies have examined the impact of KD or MCT supplementation in participants affected by mild-tomoderate AD. Four of them suggested clinical benefits in terms of short-term memory or visuo-spatial function, especially in those who did not have any APOE-e4 allele. Nevertheless all these studies included small samples of participants (N < 50) and / or short follow-up (< 3 months). - Recently a ketogenic drink showed promising results in terms of brain energy and cognition in MCI subjects. A similar nutritional intervention, in individuals with AD, was associated with improvements in cerebral blood flow using PET imaging after 45 days. Methods: Randomized controlled trial conducted in one memory center in Paris Region (Laribosière-Fernand Widal). All the participants will be included after diagnosis of AD based on comprehensive neuropsychological and clinical assessments, brain 3-Tesla MRI, FDG TEP scanner and CSF biomarkers. Trial overview: - After signing the informed consent, the participants (N=70) will be randomly assigned either to the intervention group (i.e. ketogenic diet modified Atkins 2:1) or to the control group (i.e. normal diet + nutritional advice) - Follow-up = 12 months with 3 clinicat visits: baseline, 6 and 12 months - 6 dietitian consultations in both groups (day 1, day 15, month 1, month 3, month 5, month 9) - All the visits comprise: - ketosis measure using urinary strips - cognitive assessment: MMSE, CDR - daily functioning assessment: ADSC-ADL-Pi - quality of life assessment: SF-36 - After 12 months, the participants will undergo another brain FDG PET scanner to assess change in brain metabolism. All the PET analyses will be performed by nuclear medicine physicians blinded from randomization group. - Justification of sample size: A sample size of N= 35 patients per group will allow an estimate of any adherence to KD larger or equal to 75% with a precision of at least ± 15%. In addition it will allow to estimate the mean values of the main clinical and biological endpoints of interest with a precision equal to 35% of their SD , that will allow to optimize the design and sample size calculation for a next larger RCT on this topic. - Adherence to diet and potential adverse effects will be monitored throughout the study. Ketosis achievement and ketonuria related to KD will be confirmed using urinary tests. - All the participants will be provided instructions by one study dietitians, at the 3 visits and in 3 additional consultations. Individuals from the intervention group will be given food lists and specific recommandations about ketogenic food. Nutritional advice from the National French Nutrition Programme will be given to the participants of the control group - The study protocol will be written with our Clinical Research Unit and approved by the French Ethics Committee (Comité de Protection des Personnes)


Recruitment information / eligibility

Status Recruiting
Enrollment 70
Est. completion date March 2027
Est. primary completion date March 2027
Accepts healthy volunteers No
Gender All
Age group 50 Years and older
Eligibility Inclusion Criteria: - Age >= 50 - AD confirmed by biomarkers (CSF and/or PET scan) - CDR score=0.5 or 1 - Speaking/understanding French - Presence of a caregiver Exclusion Criteria: - Diabetes - Other neurological disease - Chronic inflammatory disease or anti-inflammatory medication (e.g. NSAI, corticosteroids) - Uncontrolled dyslipidemia - Malnutrition (BMI < 18; or weight loss > 5% in 1 month or 10% in 6 months; or MNA < 17) - Severe chronic condition or organ dysfunction

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Ketogenic diet
The Atkins 2: 1 diet as prescribed for the participants of our intervention group (N = 35) is based on a diet moderately rich in protein (meat, fish, cheese, eggs, vegetable proteins) and without restriction of fats, provided they are balanced, but limiting the carbohydrate intake (bread, pasta, rice) to 50 grams / day. The ratio calories from fat / calories from protein + carbohydrates will be 3 to 1

Locations

Country Name City State
France Cognitive Neurology Center - Lariboisière Fernand Widal University Hospital (APHP) Paris

Sponsors (2)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris France Alzheimer

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Other Efficiency of ketogenic diet on Instrumental Activities of Daily Living performance To estimate the efficiency of KD on Instrumental Activities of Daily Living performance (Alzheimer's Disease Cooperative Study - Activities of Daily Living Prevention Instrument): ADCS-ADL-PI 12 months
Other Efficiency of ketogenic diet on Quality of Life To estimate the efficiency of KD on Quality of Life : SF-36 scale 12 months
Primary Feasibilty of Ketogenic diet with urinary ketone levels To assess the feasibilty of a KD, in patients affected by early AD followed for a period of 12 months, measuring urinary ketone levels. 12 months
Secondary Efficiency of ketogenic diet on cognition To estimate the efficiency of KD on cognition : CDR scale (clinical dementia rating scale from 0-normal to 3-severe) 12 months
Secondary Safety of ketogenic diet with weight To estimate the safety of KD on nutritional status : weight 12 months
Secondary Safety of ketogenic diet with albumin levels To estimate the safety of KD on nutritional status : albumin levels 12 months
Secondary Safety of ketogenic diet with lipid levels To estimate the safety of KD on nutritional status : lipid levels 12 months
Secondary Efficiency of ketogenic diet on brain metabolism To estimate the efficiency of KD on brain metabolism with FDG TEP scan 12 months
Secondary Efficiency of ketogenic diet on cognition To estimate the efficiency of KD on cognition : MMSE (Mini-Mental State Examination from 0-severe to 30-normal) 12 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03625401 - Efficacy and Safety of AD-35 in Treatment of Subjects With Mild to Moderate Alzheimer's Disease Phase 2
Recruiting NCT05983575 - A Pivotal Study of LIPUS-Brain in Patients With Early Alzheimer's Disease Phase 3
Completed NCT05989087 - The Resting-state EEG Gamma Oscillations in Alzheimer's Disease
Recruiting NCT06080659 - Network-based biOmarker Discovery of Neurodegenerative Diseases Using Multimodal Connectivity N/A
Not yet recruiting NCT06099587 - MIMA Pilot Study: MIcrostructure of the Medial Temporal Lobe in Early Alzheimer's Disease N/A
Not yet recruiting NCT05604183 - Hyperspectral Retinal Observations for the Cross-sectional Detection of Alzheimer's Disease N/A
Withdrawn NCT03514875 - Effects of Mitochondrial-targeted Antioxidant on Mild Cognitive Impairment (MCI) Patients N/A
Recruiting NCT06203106 - NYSCF Scientific Discovery Biobank
Completed NCT03706885 - Efavirenz for Patients With Alzheimer's Disease Phase 1
Active, not recruiting NCT03661034 - Study of Tolerability, Safety and Efficacy of Sensory Stimulation at Multiple Dose Levels to Improve Brain Function (Etude Study) N/A
Not yet recruiting NCT05006599 - SNIFF - 3-Week Aptar CPS Device Phase 2
Recruiting NCT02740634 - Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study N/A
Active, not recruiting NCT03069391 - The Interactive Physical and Cognitive Exercise System N/A
Recruiting NCT06268886 - Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease Phase 2
Recruiting NCT04100889 - A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Alzheimer's Disease
Recruiting NCT04656860 - Juice Plus Supplement Clinical Trial N/A
Recruiting NCT05315895 - The Dampness Syndrome of Chinese Medicine Cohort Study
Recruiting NCT04916964 - Adapted Home-based Exercise Program "T&E" (Test-and-Exercise) in Persons With Alzheimer's Disease (HOPE Trial) N/A
Recruiting NCT04804618 - Proteomics Study of Mild Cognitive Impairment and Alzheimer's Disease
Recruiting NCT04680013 - Genetic Studies in Familial Dementia